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• The fluorescence signal produced by the Protoporphyrin IX (PpIX) build up was
measured as a function of time.
• Fluorescence signal increased linearly with time during the occlusive treatment
phase.
• Faster build up was noticed for lesion located on the face region.
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Abstract
Background: Topical photodynamic therapy (PDT) is a non-invasive light based ther-
apy used to treat non-melanoma skin cancer (NMSC) and dysplasia. During PDT, the light
sensitive molecule protoporphyrin IX (PpIX) is activated, resulting in the production of sin-
glet oxygen, which subsequently leads to cell death. PpIX is metabolised from a topically
applied pro-drug and the strong fluorescence signal associated with PpIX can be utilised
as an indicator of the amount of PpIX present within the tumour tissue. In this work we
measure the build up PpIX during the occlusive treatment phase and investigate how the
PpIX production rate is affected by different lesion and patient characteristics.
Methods: Fluorescence measurements were used to investigate the build up of PpIX
within the tumour tissue during the 3 hour long occlusive treatment prior to irradiation.
The study included in vivo measurements of 38 lesions from 38 individual patients. Ac-
tinic keratosis (AK) and basal cell carcinoma (BCC) were the lesion types included in this
study. The resulting data from the study was analysed using generalised linear mixed effects
models.
Results: It was found that the surface fluorescence signal linearly increased with oc-
clusive treatment time. The predictive models suggest that there is a significant difference
in PpIX production between lesion location, however no significant difference is demon-
strated between different lesion types, gender and skin type.
Conclusions The study extends and supports previous knowledge of PpIX production
during the occlusive treatment phase.
1 Introduction
Topical photodynamic therapy (PDT) relies on the interaction between light, molecular oxygen
and a photosensitive chemical to produce singlet oxygen and other reactive oxygen species
(ROS), leading to tissue injury and death of targeted cells [1]. PDT is a well established
method for treating superficial skin lesions such as basal cell carcinoma (BCC), Bowen’s disease
(BD) and actinic keratosis (AK) [2]. During topical photodynamic therapy (PDT), the prodrug
aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) is applied topically to the skin.
After the application of the prodrug the lesion is covered with an occlusive dressing which
blocks out any ambient light. During this occlusive treatment (with a typical duration of three
hours) the prodrug diffuses through the skin and is converted to the photosensitive molecule
protoporphyrin IX (PpIX) in the tumour cells [3]. PpIX is a naturally occurring molecule which
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is produced in the mitochondria as part of the heme biosynthesis. When precursors to PpIX
such as ALA or MAL are added to the tumour cells, rate limiting steps are bypassed and an
excess amount of PpIX is selectively accumulated in the tumour cells.
Even though PDT is a well established treatment method, there is still a desire to improve the
response rate. One suggested reason for a reduced response rate is the insufficient accumulation
of PpIX within the lesional tissue [4]. Typically the occlusive treatment phase (OTP) is three
hours long, but improved results with a longer OTP have been reported [5]. The work presented
here provides a study of the production of PpIX during the OTP to determine the rate at which
PpIX builds up within the tumour tissue during the OTP where different lesion and patient
characteristics are compared.
Many skin properties change when tissue is removed from the body. Thus it is important
to consider in vivo data when investigating and representing skin dynamics during light based
therapies such as PDT. Clinical studies are vital for development of the PDT treatment as well
as determination of skin properties to allow accurate theoretical simulations. In PDT the in vivo
data acquisition is mostly limited to surface measurements, due to the non-invasive nature of the
treatment. One measurable quantity is the characteristic fluorescence signal associated with the
PpIX molecule, where the level of measured fluorescence is used as an indicator of the amount
of PpIX present within the skin tissue [6]. It is important to be aware of the limitations of the
penetration of light through tissue which means that fluorescence from depth will be attenuated
to some extent when measured at the skin surface. In this study fluorescence observations were
used to measure the production of PpIX during the OCP.
3
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2 Materials and Methods
2.1 Patients
38 patients (14 men and 24 women) between 43 and 92 years old with BCC (27 lesions) or
AK (11 lesions) were included. Skin types I - IV was examined (I: 11, II: 20, III: 5 and IV: 2).
Only one lesion per patient was included to reduce measurement correlations. The study took
place between October and December 2014 at the skin department of Amaral Carvalho Hospital
(Jau´, Brazil) and all patients underwent routine PDT after measurements were taken. The study
was approved by the University of St Andrews Teaching and Research Ethics Committee (Ref.:
PA11325) as well as the Review Board on Ethics in Research from the Amaral Carvalho Hos-
pital Foundation (Ref: CEPFCHAC 140/11). Written consent was obtained from all patients
before participating in the clinical study.
2.2 Photosensitiser
The pro-drug that was used contained 20% MAL (PDTPharma LTDA., Cravinhos-SP, Brazil)
which was converted to ALA that subsequently induced the production of PpIX within the mito-
chondria. Both ALA and PpIX are naturally occurring in human cells and are main components
in heme production. Exogenous addition of ALA leads to bypassing of rate limiting steps and
accumulation of PpIX in tumour cells [3].
2.3 Fluorescence device
The fluorescence measurements were recorded using an optical biopsy system (OBS) illustrated
in figure 1. The OBS houses a blue, 405 nm laser diode (approximately 1mW output), which is
coupled to a fibre probe (diameter of 600 µm). The probe was used both for the excitation light
as well as collecting the resulting fluorescence. A 455 nm long-pass filter and a fibre splitter are
included in the OBS to allow the excitation light and collected signal to be separated and the
4
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backscattered light from the excitation to be eliminated from the recorded spectra. The collected
light was recorded using a compact grating spectrometer (Ocean Optics, Inc.) interfaced with a
PC.
2.4 Study design
Appropriate lesions were examined and selected for the study by a qualified dermatologist. All
lesions were photographed, measured and biopsied to ensure correct identification. Before the
prodrug was added to the lesion, a curettage was applied to remove the surface crust to improve
penetration of the prodrug.The biopsy that was removed during the curettage was sent away for
analysis. After the cream application (containing MAL), the lesion was covered with a PVC
plastic film, aluminium foil and a compress, which was secured with surgical tape. The occlu-
sive dressing was applied for a total of three hours. During this OTP the fluorescence signal
was recorded at regular time intervals. At each measurement point the dressing was removed,
any excess cream was removed and the fluorescence signal was recorded from the lesion. Five
measurements from approximately the same area were recorded before the cream and dressing
was reapplied. This was repeated every 20 min for a total of 3 hours. When required, addi-
tional cream was added to the lesion to ensure that there was always an excess amount of cream
on the lesion. The fluorescence signal was also recorded prior to cream application to estab-
lish the autofluorescence from each patient/lesion. Test measurements were carried out (not
reported) which showed that the presence of MAL did not affect the penetration of light. MAL
does not emit any fluorescence light that would interfere with the measurements of the PpIX
fluorescence.
The probe was placed in light contact with and perpendicular to the skin. The measurements
were performed in a darkened environment and the probe was repositioned at approximately
the same point of the lesion to record repeated measurements. By using lesion landmarks it
5
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was possible to measure the fluorescence from approximately the same area throughout the
OTP. Most patients with AK only received one treatment, and for this reason only data from
this session was included in this work although some patients with BCC received a second
treatment. For all measurements analysed, the autofluorescence spectrum measured prior to
prodrug application was subtracted. From each resulting measurement the peak value of the
fluorescence measurement (635 nm) was obtained (figure 3) and subsequently used to analyse
the PpIX production as a function of time.
Following the occlusive treatment the lesion was treated using a therapeutic light source for
20 min [7]. The measurements were performed under such conditions that it was assumed to
not affect the build up of PpIX within the tumour lesion.
2.5 Statistical analysis
Our aim was to generate a statistical model that accurately predicts the fluorescence signal as it
changes with time for different patient characteristics such as skin type and lesion types. When
measuring a longitudinal data set, correlation between the measured data points is present. For
this reason the data points cannot be assumed to be independent and simple linear regression is
not appropriate. In addition the spread of the data was proven to not be normal nor homogenous,
which indicates that generalised statistical models are required.
A common and convenient way of modelling variation between individuals within a data
set is by adopting random effects. The random effects represent the variation not explained by
the covariates (fixed effects). The difference in, for example, genetic make up associated with
different individuals results in different PpIX production rates. This effect is not considered
within the fixed effects model and by including the random effects associated with the individual
and explaining the associated noise, the information gained from the estimated model can be
applied to the wider population and not only the small subset of patients included in the study.
6
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A mixed effects model considers the correlation between repeated measurements as well as the
longitudinal correlations [8]. This makes generalised mixed effects models (GLMMs) the most
appropriate framework to adopt in the presented study. All statistical analysis was carried out
in R [9].
3 Results
Figure 2 shows a patient with multiple BCC lesions located on the shoulder/back with typical
characteristics for the study. The size of the lesions were approximately 2 cm (left) and 1.5 cm
(right). Only one of the lesions (right) was included within the study (magnified figure 2) to
reduce correlations within the analysis. The characteristic fluorescence signal generated from
the PpIX within the lesion tissue is shown in figure 3. In the figure both the characteristics peaks
at 635 nm and 705 nm are shown. As discussed above, the work presented here focuses on the
peak at 635 nm. I.e. the fluorescence value at the peak at 635 nm was used as the indicator of
the PpIX distribution within the lesion.
An initial analysis showed that the data collected here gives the linear trend that has pre-
viously been suggested [10, 11]. For this reason the adopted model was assumed to follow
a positive linear trend. Since all data points were background subtracted, the y-intercept was
forced to the origin. The skewness of the residuals in combination with the requirement of a
positive continuous model indicates a Gamma distribution of the observations, where the vari-
ance increases quadratically with expectations [8, 12].
To consider the correlations as well as random effects, a GLMM was adopted using the
’glmmPQL’ function in the ’MASS’ package in R. The explanatory variables that were in-
vestigated were: gender, location of the lesion, skin type and type of lesion. During the first
treatment session the results show that there was no significant difference associated with gen-
der, skin type or lesion type. However, the GLMM showed that there was a signifiant difference
7
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(p < 0.05) in lesion location. Lesions located on the face/head area shows a faster increase of
PpIX production during the occlusive treatment face compared to other lesion locations. Figure
4 shows the linear trends associated with the lesion locations.
4 Discussion
Our results suggested that the strength of the fluorescence signal is affected by the location
of the lesion supporting previous findings [13, 14]. Other characteristics such as lesion type,
gender and skin type did not show any significant difference. The effect of gender and skin
type could be explained by the fact that these should not have an effect on the lesion itself. A
more significant difference between lesion type (when comparing AK and BCC) was expected
both due to the potential anatomical and physiological variation between lesion types as well as
previous published results [10]. In addition the difference in diffusion barrier between different
individuals (affected by both lesion type and location of the lesion) will influence the penetration
of the prodrug and thereby the distribution of the PpIX. However, no significant difference was
found within the data obtained within this study.
Since the light source in the OBS is blue, the penetration of this light is as previously men-
tioned, limited. This means that the whole depth of the lesion might not be measured success-
fully. PpIX from depths beyond the measuring range will therefore not contribute to this study.
To remove this limitation further investigations are encouraged. This would include measure-
ments of biopsied sample sections as well as using alternative deeper penetrating light sources
to measure the fluorescence.
The linear trend was found to be an appropriate fit for our data and is, as previously men-
tioned, supported by previous studies [10, 11]. There is no way of determining the trend after
the three hours of occlusive treatment. It could be argued that the linear trend would flatten
out if the occlusive treatment was extended due to the saturation of the PpIX. To measure this,
8
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the subjects would have to stay in the clinic for a longer period of time and the PDT treatment
would not be able to be performed according to the regulated protocol. In a previous study,
where the fluorescence was studied in healthy human skin, no significance was observed when
ALA was applied for 1 hours or 6 hours. This shows that the differences between NMSC and
healthy skin modifies the PpIX production kinetics [15].
The results show a large variation within patients as well as between patients. This could
be explained by the non-uniform nature of tumour tissue. Even though the same area was
targeted for the repeated measurements, non-uniformities on small size-scales can lead to large
variations in the fluorescence signal [16].
Due to the slight variation in surface preparation (degree of curettage) between institutes a
study which considers this would be appropriate. Including several institutes would strengthen
the results and increase the number of patients included in the study.
The statistical framework that was developed for this study should be considered for other
clinical studies. By considering the correlation, more appropriate results and conclusions can
be drawn from clinical data. The collected data extends the previous knowledge where the
frequency of measurements was increased as well as the comparison between more explanatory
variables, has to our knowledge, not previously been undertaken.
5 Conclusion
The PpIX fluorescence signal from patients presented with superficial skin lesions (BCC and
AK) was measured at a regular time interval during a three hour long OTP. It was found that the
PpIX increased linearly during the first three hours of the occlusive phase where results indicate
a larger overall amount of PpIX produced in lesions located on the face compared to all other
body location. Even though the results show a large variability both intra- and inter-subject,
the linear trend supports previously published data. This study extends and supports previous
9
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knowledge of PpIX production during the occlusive treatment phase.
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Figure 1: Schematics of the optical biopsy system (OBS) where all components, except for
the laptop computer are eclipsed within a box to prevent any stray light effecting the measure-
ments.
Figure 2: Image of typical lesions included within the study. Two superficial BCCs are
displayed in the image. Only the lesion to the right (magnified) was included within the study.
Figure 3: Figure showing a typical fluorescence signal (arbitrary units (a.u.) ) observed
from one of the patients included within the study. The fluorescence signal is generated when
the PpIX is exposed to blue, 405 nm, light. The fluorescence spectrum displays two character-
istic peaks at 635 nm and 705 nm. In the analysis presented here, the focus lies within the peak
at 635 nm.
Figure 4: Generalized Linear Mixed Effects Model (first session).Figure showing the lin-
ear trend between the fluorescence signal (arbitrary units, a.u.) and time (minutes) for the first
treatment. The predicted model was generated using a Generalised Linear Mixed Effects Model
(GLMM) where the results demonstrate a significant difference (p<0.05) between lesions lo-
cated on the face (dashed) compared to other body sites (solid). The fluorescence was shown to
be higher for lesions located on the face (dashed). Repeated measurements were averages to re-
duce clutter on the graph. However all repeated (five) measurements were used to fit the model.
The black circles represents lesions located on other body sites other than the face and the black
crosses corresponds to observations from lesions on the face. The confidence intervals (dotted
for lesion located on the face and dash-dot for lesion) are included for the different situations
(Note overlap between confidence intervals between the two sub-groups).
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